$NVRO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEVRO CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NEVRO CORP. Get notifications about new insider transactions in NEVRO CORP for free.
Page: < prev 1 2 3 4 5 6 ... 6 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 2,782 | 175,906 | 17,718 | |
Jan 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 120.00 | 2,782 | 333,840 | 53,490 | 56.3 K to 53.5 K (-4.94 %) |
Jan 08 2020 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 2,782 | 175,906 | 56,272 | 53.5 K to 56.3 K (+5.20 %) |
Jan 06 2020 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Payment of Exercise | F | 118.01 | 932 | 109,985 | 27,271 | 28.2 K to 27.3 K (-3.30 %) |
Dec 20 2019 | NVRO | NEVRO CORP | GROSSMAN D KEITH | President & CEO | Payment of Exercise | F | 111.50 | 4,507 | 502,531 | 99,491 | 104 K to 99.5 K (-4.33 %) |
Dec 18 2019 | NVRO | NEVRO CORP | Prange Karen | Director | Grant | A | 0.00 | 2,703 | 0 | 2,703 | 0 to 2.7 K |
Nov 26 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 12,000 | 758,760 | 20,500 | |
Nov 26 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 110.39 | 12,000 | 1,324,714 | 53,490 | 65.5 K to 53.5 K (-18.32 %) |
Nov 26 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 12,000 | 758,760 | 65,490 | 53.5 K to 65.5 K (+22.43 %) |
Nov 26 2019 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Sell | S | 110.00 | 1,000 | 110,000 | 24,073 | 25.1 K to 24.1 K (-3.99 %) |
Nov 13 2019 | NVRO | NEVRO CORP | McCormick Shawn | Director | Sell | S | 104.35 | 800 | 83,480 | 7,416 | 8.2 K to 7.4 K (-9.74 %) |
Nov 13 2019 | NVRO | NEVRO CORP | McCormick Shawn | Director | Sell | S | 104.35 | 800 | 83,480 | 7,416 | 8.2 K to 7.4 K (-9.74 %) |
Nov 13 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 104.68 | 4,610 | 482,572 | 429,519 | 434.1 K to 429.5 K (-1.06 %) |
Nov 13 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 104.68 | 4,610 | 482,572 | 429,519 | 434.1 K to 429.5 K (-1.06 %) |
Nov 13 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 103.72 | 37,116 | 3,849,779 | 434,129 | 471.2 K to 434.1 K (-7.88 %) |
Nov 13 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 103.72 | 37,116 | 3,849,779 | 434,129 | 471.2 K to 434.1 K (-7.88 %) |
Nov 13 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 103.07 | 8,274 | 852,812 | 471,245 | 479.5 K to 471.2 K (-1.73 %) |
Nov 13 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Sell | S | 103.07 | 8,274 | 852,812 | 471,245 | 479.5 K to 471.2 K (-1.73 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 12,000 | 758,760 | 32,500 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 63.23 | 12,000 | 758,760 | 32,500 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 6,522 | 117,396 | 14,941 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 6,522 | 117,396 | 14,941 | |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 104.75 | 1,175 | 123,075 | 53,490 | 54.7 K to 53.5 K (-2.15 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 104.75 | 1,175 | 123,075 | 53,490 | 54.7 K to 53.5 K (-2.15 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.85 | 10,345 | 1,074,287 | 54,665 | 65 K to 54.7 K (-15.91 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.85 | 10,345 | 1,074,287 | 54,665 | 65 K to 54.7 K (-15.91 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.31 | 7,002 | 723,369 | 65,010 | 72 K to 65 K (-9.72 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 103.31 | 7,002 | 723,369 | 65,010 | 72 K to 65 K (-9.72 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 12,000 | 758,760 | 72,012 | 60 K to 72 K (+20.00 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 63.23 | 12,000 | 758,760 | 72,012 | 60 K to 72 K (+20.00 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 6,522 | 117,396 | 60,012 | 53.5 K to 60 K (+12.19 %) |
Nov 13 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 6,522 | 117,396 | 60,012 | 53.5 K to 60 K (+12.19 %) |
Nov 08 2019 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Sell | S | 100.00 | 1,000 | 100,000 | 25,073 | 26.1 K to 25.1 K (-3.84 %) |
Nov 05 2019 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Payment of Exercise | F | 86.63 | 1,562 | 135,316 | 18,658 | 20.2 K to 18.7 K (-7.73 %) |
Nov 05 2019 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Payment of Exercise | F | 86.63 | 1,404 | 121,629 | 28,203 | 29.6 K to 28.2 K (-4.74 %) |
Nov 05 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 86.63 | 1,713 | 148,397 | 53,490 | 55.2 K to 53.5 K (-3.10 %) |
Nov 05 2019 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Payment of Exercise | F | 86.63 | 1,252 | 108,461 | 19,570 | 20.8 K to 19.6 K (-6.01 %) |
Nov 05 2019 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Payment of Exercise | F | 86.63 | 1,562 | 135,316 | 26,073 | 27.6 K to 26.1 K (-5.65 %) |
Oct 02 2019 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 183 | 0 | 10,399 | 10.2 K to 10.4 K (+1.79 %) |
Oct 02 2019 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 194 | 0 | 37,560 | 37.4 K to 37.6 K (+0.52 %) |
Oct 02 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 305 | 0 | 479,519 | 479.2 K to 479.5 K (+0.06 %) |
Sep 20 2019 | NVRO | NEVRO CORP | GROSSMAN D KEITH | President & CEO | Payment of Exercise | F | 89.31 | 3,912 | 349,381 | 103,998 | 107.9 K to 104 K (-3.63 %) |
Aug 06 2019 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Payment of Exercise | F | 64.57 | 864 | 55,788 | 20,822 | 21.7 K to 20.8 K (-3.98 %) |
Jul 17 2019 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Option Exercise | A | 64.95 | 71,575 | 4,648,796 | 71,575 | |
Jul 17 2019 | NVRO | NEVRO CORP | Pellegrini Niamh Louise | Chief Commercial Of ... | Grant | A | 0.00 | 33,175 | 0 | 33,175 | 0 to 33.2 K |
Jul 17 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 3.60 | 2,500 | 9,000 | 41,394 | |
Jul 17 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 3.60 | 2,500 | 9,000 | 55,203 | 52.7 K to 55.2 K (+4.74 %) |
Jun 21 2019 | NVRO | NEVRO CORP | GROSSMAN D KEITH | President & CEO | Payment of Exercise | F | 64.40 | 3,201 | 206,144 | 107,910 | 111.1 K to 107.9 K (-2.88 %) |
Jun 10 2019 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Buy | P | 60.99 | 2,460 | 150,027 | 14,883 | 12.4 K to 14.9 K (+19.80 %) |
Jun 10 2019 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Buy | P | 61.45 | 4,128 | 253,677 | 12,423 | 8.3 K to 12.4 K (+49.76 %) |
Jun 10 2019 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Buy | P | 60.99 | 1,595 | 97,277 | 8,295 | 6.7 K to 8.3 K (+23.81 %) |
Jun 07 2019 | NVRO | NEVRO CORP | OBOYLE KEVIN C | Director | Buy | P | 60.00 | 1,675 | 100,500 | 8,375 | 6.7 K to 8.4 K (+25.00 %) |
May 30 2019 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Grant | A | 0.00 | 3,425 | 0 | 29,607 | 26.2 K to 29.6 K (+13.08 %) |
May 30 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Grant | A | 0.00 | 8,564 | 0 | 52,703 | 44.1 K to 52.7 K (+19.40 %) |
May 22 2019 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 6,049 | 0 | 6,700 | 651 to 6.7 K (+929.19 %) |
May 22 2019 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 2,913 | 0 | 10,216 | 7.3 K to 10.2 K (+39.89 %) |
May 22 2019 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 2,913 | 0 | 479,214 | 476.3 K to 479.2 K (+0.61 %) |
May 22 2019 | NVRO | NEVRO CORP | OBOYLE KEVIN C | Director | Grant | A | 0.00 | 6,049 | 0 | 6,700 | 651 to 6.7 K (+929.19 %) |
May 22 2019 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Grant | A | 0.00 | 2,913 | 0 | 8,216 | 5.3 K to 8.2 K (+54.93 %) |
May 22 2019 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 2,913 | 0 | 37,366 | 34.5 K to 37.4 K (+8.45 %) |
May 22 2019 | NVRO | NEVRO CORP | McCormick Shawn | Director | Grant | A | 0.00 | 2,913 | 0 | 8,216 | 5.3 K to 8.2 K (+54.93 %) |
Apr 09 2019 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Payment of Exercise | F | 64.17 | 389 | 24,962 | 20,220 | 20.6 K to 20.2 K (-1.89 %) |
Mar 21 2019 | NVRO | NEVRO CORP | GROSSMAN D KEITH | President & CEO | Grant | A | 0.00 | 111,111 | 0 | 111,111 | 0 to 111.1 K |
Mar 21 2019 | NVRO | NEVRO CORP | WEATHERMAN ELIZABETH H | Director | Grant | A | 0.00 | 651 | 0 | 651 | 0 to 651 |
Mar 21 2019 | NVRO | NEVRO CORP | OBOYLE KEVIN C | Director | Grant | A | 0.00 | 651 | 0 | 651 | 0 to 651 |
Mar 07 2019 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Option Exercise | M | 42.30 | 1,031 | 43,611 | 15,469 | |
Mar 07 2019 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Buy | M | 42.30 | 1,031 | 43,611 | 27,016 | 26 K to 27 K (+3.97 %) |
Feb 22 2019 | NVRO | NEVRO CORP | Carter Michael Collier | Vice President, Sal ... | Option Exercise | A | 48.44 | 78,700 | 3,812,228 | 78,700 | |
Feb 22 2019 | NVRO | NEVRO CORP | Carter Michael Collier | Vice President, Sal ... | Grant | A | 0.00 | 39,350 | 0 | 39,350 | 0 to 39.4 K |
Jan 08 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 11,004 | 15,846 | 0 | |
Jan 08 2019 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 11,004 | 15,846 | 44,139 | 33.1 K to 44.1 K (+33.21 %) |
Jan 07 2019 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Payment of Exercise | F | 35.52 | 2,898 | 102,937 | 122,387 | 125.3 K to 122.4 K (-2.31 %) |
Jan 04 2019 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Payment of Exercise | F | 36.55 | 1,022 | 37,354 | 25,561 | 26.6 K to 25.6 K (-3.84 %) |
Nov 29 2018 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Option Exercise | A | 42.30 | 11,000 | 465,300 | 11,000 | |
Nov 29 2018 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Grant | A | 0.00 | 5,500 | 0 | 21,686 | 16.2 K to 21.7 K (+33.98 %) |
Nov 29 2018 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | A | 42.30 | 16,500 | 697,950 | 16,500 | |
Nov 29 2018 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Grant | A | 0.00 | 8,250 | 0 | 20,609 | 12.4 K to 20.6 K (+66.75 %) |
Nov 29 2018 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Option Exercise | A | 42.30 | 16,500 | 697,950 | 16,500 | |
Nov 29 2018 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Grant | A | 0.00 | 8,250 | 0 | 25,985 | 17.7 K to 26 K (+46.52 %) |
Nov 29 2018 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Option Exercise | A | 42.30 | 32,500 | 1,374,750 | 32,500 | |
Nov 29 2018 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Grant | A | 0.00 | 16,250 | 0 | 26,250 | 10 K to 26.3 K (+162.50 %) |
Nov 02 2018 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Payment of Exercise | F | 49.40 | 849 | 41,941 | 12,359 | 13.2 K to 12.4 K (-6.43 %) |
Nov 02 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 49.40 | 2,457 | 121,376 | 33,135 | 35.6 K to 33.1 K (-6.90 %) |
Nov 02 2018 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Payment of Exercise | F | 49.40 | 4,368 | 215,779 | 125,285 | 129.7 K to 125.3 K (-3.37 %) |
Nov 02 2018 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Payment of Exercise | F | 49.40 | 777 | 38,384 | 16,186 | 17 K to 16.2 K (-4.58 %) |
Nov 02 2018 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Payment of Exercise | F | 49.40 | 849 | 41,941 | 17,735 | 18.6 K to 17.7 K (-4.57 %) |
Sep 19 2018 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Option Exercise | M | 3.60 | 18,400 | 66,240 | 101,146 | |
Sep 19 2018 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Buy | M | 3.60 | 18,400 | 66,240 | 129,653 | 111.3 K to 129.7 K (+16.54 %) |
Aug 06 2018 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Payment of Exercise | F | 59.55 | 864 | 51,451 | 16,963 | 17.8 K to 17 K (-4.85 %) |
Aug 03 2018 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Option Exercise | M | 53.70 | 1,000 | 53,700 | 34,000 | |
Aug 03 2018 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Buy | M | 53.70 | 1,000 | 53,700 | 18,584 | 17.6 K to 18.6 K (+5.69 %) |
Jul 26 2018 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Option Exercise | M | 53.70 | 1,500 | 80,550 | 35,000 | |
Jul 26 2018 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Buy | M | 53.70 | 1,500 | 80,550 | 17,584 | 16.1 K to 17.6 K (+9.33 %) |
Jul 20 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 7,400 | 10,656 | 11,004 | |
Jul 20 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 7,400 | 10,656 | 35,592 | 28.2 K to 35.6 K (+26.25 %) |
Jun 05 2018 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Payment of Exercise | F | 77.44 | 7,894 | 611,311 | 111,253 | 119.1 K to 111.3 K (-6.63 %) |
May 23 2018 | NVRO | NEVRO CORP | Vale Brad | Director | Grant | A | 0.00 | 3,785 | 0 | 7,303 | 3.5 K to 7.3 K (+107.59 %) |
May 23 2018 | NVRO | NEVRO CORP | McCormick Shawn | Director | Grant | A | 0.00 | 3,785 | 0 | 5,303 | 1.5 K to 5.3 K (+249.34 %) |
May 23 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Grant | A | 0.00 | 3,785 | 0 | 5,303 | 1.5 K to 5.3 K (+249.34 %) |
May 23 2018 | NVRO | NEVRO CORP | Fischer Frank M | Director | Grant | A | 0.00 | 3,785 | 0 | 34,453 | 30.7 K to 34.5 K (+12.34 %) |
May 23 2018 | NVRO | NEVRO CORP | Earnhardt Lisa D | Director | Grant | A | 0.00 | 3,785 | 0 | 5,303 | 1.5 K to 5.3 K (+249.34 %) |
May 23 2018 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Grant | A | 0.00 | 3,785 | 0 | 476,301 | 472.5 K to 476.3 K (+0.80 %) |
May 23 2018 | NVRO | NEVRO CORP | Behbahani Ali | Director | Grant | A | 0.00 | 3,785 | 0 | 5,390 | 1.6 K to 5.4 K (+235.83 %) |
May 23 2018 | NVRO | NEVRO CORP | Behbahani Ali | Director | Grant | A | 0.00 | 3,785 | 0 | 5,390 | 1.6 K to 5.4 K (+235.83 %) |
May 16 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 7,000 | 126,000 | 21,463 | |
May 16 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 76.14 | 7,000 | 532,959 | 28,192 | 35.2 K to 28.2 K (-19.89 %) |
May 16 2018 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 7,000 | 126,000 | 35,192 | 28.2 K to 35.2 K (+24.83 %) |
May 15 2018 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 18.00 | 3,631 | 65,358 | 80,291 | |
May 15 2018 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Buy | M | 18.00 | 3,631 | 65,358 | 472,516 | 468.9 K to 472.5 K (+0.77 %) |
Apr 09 2018 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Payment of Exercise | F | 88.69 | 389 | 34,500 | 13,208 | 13.6 K to 13.2 K (-2.86 %) |
Mar 07 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 81.42 | 1,461 | 118,958 | 11,042 | 12.5 K to 11 K (-11.69 %) |
Mar 07 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 81.42 | 66,125 | 5,384,043 | 500,109 | 566.2 K to 500.1 K (-11.68 %) |
Mar 07 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 80.38 | 1,098 | 88,258 | 12,503 | 13.6 K to 12.5 K (-8.07 %) |
Mar 07 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 80.38 | 49,742 | 3,998,297 | 566,234 | 616 K to 566.2 K (-8.08 %) |
Mar 07 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 80.19 | 910 | 72,969 | 13,601 | 14.5 K to 13.6 K (-6.27 %) |
Mar 07 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 80.19 | 41,206 | 3,304,144 | 615,976 | 657.2 K to 616 K (-6.27 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 80.48 | 216 | 17,385 | 14,511 | 14.7 K to 14.5 K (-1.47 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 80.48 | 9,784 | 787,458 | 657,182 | 667 K to 657.2 K (-1.47 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 81.36 | 151 | 12,286 | 14,727 | 14.9 K to 14.7 K (-1.01 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 81.36 | 6,832 | 555,869 | 666,966 | 673.8 K to 667 K (-1.01 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 83.09 | 173 | 14,375 | 14,878 | 15.1 K to 14.9 K (-1.15 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 83.09 | 7,844 | 651,791 | 673,798 | 681.6 K to 673.8 K (-1.15 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 83.20 | 286 | 23,795 | 15,051 | 15.3 K to 15.1 K (-1.86 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 83.20 | 12,972 | 1,079,243 | 681,642 | 694.6 K to 681.6 K (-1.87 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.17 | 26 | 2,188 | 15,337 | 15.4 K to 15.3 K (-0.17 %) |
Mar 01 2018 | NVRO | NEVRO CORP | JAEGER WILFRED E | Director | Sell | S | 84.17 | 1,174 | 98,819 | 694,614 | 695.8 K to 694.6 K (-0.17 %) |
Jan 05 2018 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Payment of Exercise | F | 71.17 | 3,019 | 214,862 | 119,147 | 122.2 K to 119.1 K (-2.47 %) |
Dec 22 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Option Exercise | M | 3.60 | 41,572 | 149,659 | 0 | |
Dec 22 2017 | NVRO | NEVRO CORP | DEMANE MICHAEL F | Director | Buy | M | 3.60 | 41,572 | 149,659 | 468,885 | 427.3 K to 468.9 K (+9.73 %) |
Dec 20 2017 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Option Exercise | A | 70.86 | 20,000 | 1,417,200 | 20,000 | |
Dec 20 2017 | NVRO | NEVRO CORP | Rashid Kashif | General Counsel | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Dec 14 2017 | NVRO | NEVRO CORP | Alecxih James | Vice President, Sal ... | Option Exercise | A | 66.26 | 45,000 | 2,981,700 | 45,000 | |
Dec 14 2017 | NVRO | NEVRO CORP | Alecxih James | Vice President, Sal ... | Grant | A | 0.00 | 12,000 | 0 | 12,000 | 0 to 12 K |
Nov 16 2017 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Option Exercise | A | 76.81 | 13,000 | 998,530 | 13,000 | |
Nov 16 2017 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Grant | A | 0.00 | 6,500 | 0 | 13,597 | 7.1 K to 13.6 K (+91.59 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Option Exercise | A | 76.81 | 13,000 | 998,530 | 13,000 | |
Nov 16 2017 | NVRO | NEVRO CORP | Christoforou Christofer | VP, Research & Deve ... | Grant | A | 0.00 | 6,500 | 0 | 17,827 | 11.3 K to 17.8 K (+57.39 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Option Exercise | A | 76.81 | 13,000 | 998,530 | 13,000 | |
Nov 16 2017 | NVRO | NEVRO CORP | Alleavitch Doug | VP, Quality | Grant | A | 0.00 | 6,500 | 0 | 15,766 | 9.3 K to 15.8 K (+70.15 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 18.00 | 7,000 | 126,000 | 35,463 | |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | A | 76.81 | 26,000 | 1,997,060 | 26,000 | |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Sell | S | 75.11 | 7,000 | 525,740 | 28,192 | 35.2 K to 28.2 K (-19.89 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 18.00 | 7,000 | 126,000 | 35,192 | 28.2 K to 35.2 K (+24.83 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Grant | A | 0.00 | 13,000 | 0 | 28,192 | 15.2 K to 28.2 K (+85.57 %) |
Nov 16 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Option Exercise | M | 76.81 | 70,500 | 5,415,105 | 70,500 | |
Nov 16 2017 | NVRO | NEVRO CORP | Elghandour Rami | President & CEO | Grant | A | 0.00 | 35,250 | 0 | 122,166 | 86.9 K to 122.2 K (+40.56 %) |
Nov 13 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Option Exercise | M | 1.44 | 4,000 | 5,760 | 18,404 | |
Nov 13 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Buy | M | 1.44 | 4,000 | 5,760 | 15,192 | 11.2 K to 15.2 K (+35.74 %) |
Nov 03 2017 | NVRO | NEVRO CORP | Schmitz Patrick | Vice President, Ope ... | Payment of Exercise | F | 88.99 | 313 | 27,854 | 7,097 | 7.4 K to 7.1 K (-4.22 %) |
Nov 03 2017 | NVRO | NEVRO CORP | Galligan Andrew H | Chief Financial Off ... | Payment of Exercise | F | 88.99 | 641 | 57,043 | 11,192 | 11.8 K to 11.2 K (-5.42 %) |